The 36th Annual Meeting of the Society for Medical Decision Making: Concurrent Oral Sessions

Category Reference for Presentations
DECDecision Psychology and Shared Decision Making AHEApplied Health Economics
HSPHealth Services and Policy Research METQuantitative Methods and Theoretical Developments
PFAPreference Assessment
* Candidate for the Lee B. Lusted Student Prize Competition

Monday, October 20, 2014, Day One
10:00 - 11:30 AM
Attendees are invited to move from room-to-room
Room
Session Title TRA-1. CONCURRENT PRESENTATIONS OF TOP RATED ABSTRACTS I: PREFERENCE AND DECISION MAKING Click to view session TRA-2. CONCURRENT PRESENTATIONS OF TOP RATED ABSTRACTS II: MODELING AND POPULATION HEALTH Click to view session
10:00 - 10:15 TRA-1-1* (DEC) SOCIAL NORMATIVE BELIEFS ARE CENTRAL TO.. TRA-1-1* (DEC) SOCIAL NORMATIVE BELIEFS ARE CENTRAL TO PATIENT CHOICE TO INTENSIFY THERAPY IN RHEUMATOID ARTHRITIS TRA-2-1 (AHE) COST-EFFECTIVENESS ANALYSIS OF CYP2B6 GENETIC.. TRA-2-1 (AHE) COST-EFFECTIVENESS ANALYSIS OF CYP2B6 GENETIC TESTING TO INFORM EFAVIRENZ DOSE REDUCTION FOR INITIAL HIV THERAPY
10:15 - 10:30 TRA-1-2* (DEC) TRANSPARENCY ABOUT BENEFITS AND HARMS IS.. TRA-1-2* (DEC) TRANSPARENCY ABOUT BENEFITS AND HARMS IS UNCOMMON IN RECOMMENDATIONS ON CANCER SCREENING & PREVENTION TRA-2-2 (HSP) VARIABILITY IN REVASCULARIZATION TREATMENT.. TRA-2-2 (HSP) VARIABILITY IN REVASCULARIZATION TREATMENT DECISIONS AMONG HOSPITALS AND ITS ASSOCIATION WITH SURGICAL MORTALITY
10:30 - 10:45 TRA-1-3 (DEC) USING CONJOINT ANALYSIS TO ASSESS THE RELATIVE.. TRA-1-3 (DEC) USING CONJOINT ANALYSIS TO ASSESS THE RELATIVE INFLUENCE OF RESUSCITATION PREFERENCES ON OBSTETRICAL MANAGEMENT OF PERIVIABLE DELIVERIES TRA-2-3 (MET) A NOVEL BIVARIATE BETA DISTRIBUTION CONSTRUCTE.. TRA-2-3 (MET) A NOVEL BIVARIATE BETA DISTRIBUTION CONSTRUCTED FROM THE DIRICHLET DISTRIBUTION
10:45 - 11:00 TRA-1-4 (DEC) HOW PATIENTS' PRIMARY TREATMENT CHOICES FOR.. TRA-1-4 (DEC) HOW PATIENTS' PRIMARY TREATMENT CHOICES FOR LOCALIZED PROSTATE CANCER SHIFT WITH PATIENTS' DIFFERENT PREFERENCES ON SIDE EFFECTS TRA-2-4 (MET) A PROGRESSIVE CALIBRATION PROCEDURE FOR.. TRA-2-4 (MET) A PROGRESSIVE CALIBRATION PROCEDURE FOR INDIVIDUALIZED COLORECTAL CANCER SCREENING STUDY
11:00 - 11:15 TRA-1-5 (PFA) WHERE PATIENTS STAND DEPENDS ON WHERE THEY.. TRA-1-5 (PFA) WHERE PATIENTS STAND DEPENDS ON WHERE THEY SIT: CURRENT HEALTH STATUS AND TOLERANCE FOR THERAPEUTIC RISKS TRA-2-5 (MET) *TOP RANKED ABSTRACT AT THE 15TH BIENNIAL.. TRA-2-5 (MET) *TOP RANKED ABSTRACT AT THE 15TH BIENNIAL EUROPEAN MEETING* COMBINING MARKOV STATES: A COMPARISON OF ANALYTICAL AND HEURISTIC METHODS FOR DERIVING THE HAZARD RATES OF A COLLAPSED MARKOV STATE
11:15 - 11:30 TRA-1-6 (DEC) *TOP RANKED ABSTRACT AT THE 2014 ASIA -.. TRA-1-6 (DEC) *TOP RANKED ABSTRACT AT THE 2014 ASIA - PACIFIC CONFERENCE* CONCORDANCE IN PREFERENCES FOR END OF LIFE CARE BETWEEN ADVANCED CANCER PATIENTS AND THEIR CAREGIVERS IN SINGAPORE: A DISCRETE CHOICE EXPERIMENT TRA-2-6 (PFA) CHANGES IN HEALTH-RELATED QUALITY OF LIFE.. TRA-2-6 (PFA) CHANGES IN HEALTH-RELATED QUALITY OF LIFE AMONG CANCER SURVIVORS: A POPULATION ANALYSIS
1:00 - 2:30 PM
Attendees are invited to move from room-to-room
Room
Session Title 1A. ESTIMATING & APPLYING COSTS: AN INTERNATIONAL SESSION Click to view session 1B. PREFERENCE ASSESSMENT AND OTHER EVALUATION METHODS Click to view session 1C. COST ANALYSES AND CLINICAL PRACTICE Click to view session
1:00 - 1:15 1A-1 (AHE) ESTIMATING INDIVIDUAL MEDICAL EXPENDITURES.. 1A-1 (AHE) ESTIMATING INDIVIDUAL MEDICAL EXPENDITURES FROM HOUSEHOLD SURVEYS IN THE CONTEXT OF URBANIZATION AND ECONOMIC DEVELOPMENT: INDIA, 1995-2010 1B-1 (PFA) THE VALUE OF FAME AND SHAME: DRUG-DIVERSION.. 1B-1 (PFA) THE VALUE OF FAME AND SHAME: DRUG-DIVERSION INCENTIVES AND DISINCENTIVES IN SPORT 1C-1 (HSP) PRICING IN THE MARKET FOR ANTICANCER DRUGS 1C-1 (HSP) PRICING IN THE MARKET FOR ANTICANCER DRUGS
1:15 - 1:30 1A-2 (AHE) ESTIMATING THE COSTS ASSOCIATED WITH.. 1A-2 (AHE) ESTIMATING THE COSTS ASSOCIATED WITH MENINGOCOCCAL OUTBREAKS IN BRAZIL AND COLOMBIA 1B-2 (PFA) VALUING PREFERENCES FOR THE PROCESS AND.. 1B-2 (PFA) VALUING PREFERENCES FOR THE PROCESS AND OUTCOME OF CLINICAL GENETICS SERVICES: A PILOT STUDY 1C-2 (HSP) PATTERNS OF COST-RELATED MEDICATION NON-ADHERE.. 1C-2 (HSP) PATTERNS OF COST-RELATED MEDICATION NON-ADHERENCE AMONG OLDER PATIENTS AT HIGH RISK OF HOSPITALIZATION
1:30 - 1:45 1A-3 (AHE) COST EFFECTIVENESS OF THE NEW MEDICINE SERVICE.. 1A-3 (AHE) COST EFFECTIVENESS OF THE NEW MEDICINE SERVICE IN COMMUNITY PHARMACIES IN ENGLAND 1B-3 (PFA) MODELING INDIVIDUAL UTILITY FROM COLORECTAL.. 1B-3 (PFA) MODELING INDIVIDUAL UTILITY FROM COLORECTAL CANCER SCREENING 1C-3 (HSP) ASSESSING THE PERFORMANCE OF ART DELIVERY: A.. 1C-3 (HSP) ASSESSING THE PERFORMANCE OF ART DELIVERY: A COSTS EFFICIENCY ANALYSIS OF THE MEXICAN HIV PROGRAM
1:45 - 2:00 1A-4 (AHE) ANALYSIS OF HEALTHCARE COSTS IN PATIENTS WITH.. 1A-4 (AHE) ANALYSIS OF HEALTHCARE COSTS IN PATIENTS WITH ACUTE WHIPLASH-ASSOCIATED DISORDERS USING ZERO-ADJUSTED GAMMA MODELS 1B-4 (PFA) A FRAMEWORK FOR DIFFERENTIATING BETWEEN HEALTH.. 1B-4 (PFA) A FRAMEWORK FOR DIFFERENTIATING BETWEEN HEALTH IMPROVEMENTS AND IMPAIRMENTS IN QALY-ANALYSES 1C-4 (HSP) COGNITIVE INERTIA AND TECHNOLOGICAL ABANDONMEN.. 1C-4 (HSP) COGNITIVE INERTIA AND TECHNOLOGICAL ABANDONMENT IN MEDICINE
2:00 - 2:15 1A-6 (AHE) DYNAMICS IN THE COSTS OF CRIMINALITY AMONG.. 1A-6 (AHE) DYNAMICS IN THE COSTS OF CRIMINALITY AMONG OPIOID DEPENDENT INDIVIDUALS 1B-5 (PFA) EMPIRICAL EVALUATION OF THE ACCEPTABLE REGRET.. 1B-5 (PFA) EMPIRICAL EVALUATION OF THE ACCEPTABLE REGRET MODEL OF MEDICAL DECISION- MAKING 1C-5 (MET) SYSTEMATICALLY-DEVELOPED GUIDANCE FOR THE.. 1C-5 (MET) SYSTEMATICALLY-DEVELOPED GUIDANCE FOR THE CONDUCT AND REPORTING OF DECISION AND SIMULATION MODELS
2:15 - 2:30 1B-6 (PFA) BEST-WORST SCALING ALLOWS US TO QUANTIFY.. 1B-6 (PFA) BEST-WORST SCALING ALLOWS US TO QUANTIFY ATTITUDES AS WELL AS PREFERENCES; RESPONSE TIMES TELL US WHICH ARE "GUT" ATTITUDES WITH NO PREDICTIVE POWER 1C-6 (MET) WHOSE QALYS COUNT IN COST-EFFECTIVENESS.. 1C-6 (MET) WHOSE QALYS COUNT IN COST-EFFECTIVENESS ANALYSES? EVALUATING INTERVENTIONS THAT AFFECT FERTILITY AND CHILDBEARING
4:15 - 5:30 PM
Attendees are invited to move from room-to-room
Room
Session Title 2D. THEORETICAL ADVANCES IN MODELING METHODS Click to view session 2E. VACCINES: DECISION MAKING, POLICY, AND CLINICAL TRIALS Click to view session 2F. BREAST CANCER: DECISION MAKING, COSTS, AND POLICY Click to view session
4:15 - 4:30 2D-1 (MET) HANDLING MISSING DATA IN META-ANALYSIS OF.. 2D-1 (MET) HANDLING MISSING DATA IN META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA WITH MIXED OUTCOMES 2E-1 (DEC) PARENTAL RISK PERCEPTION AND DECISION MAKING.. 2E-1 (DEC) PARENTAL RISK PERCEPTION AND DECISION MAKING REGARDING VACCINATION OF THEIR ELIGIBLE CHILDREN WITH THE HUMAN PAPILLOMAVIRUS VACCINE 2F-1 (HSP) COST AND POLICY IMPLICATIONS OF ADOPTION OF.. 2F-1 (HSP) COST AND POLICY IMPLICATIONS OF ADOPTION OF NEW RADIOTHERAPY TECHNOLOGY FOR BREAST CANCER
4:30 - 4:45 2D-2 (MET) EVALUATING DIFFERENT APPROACHES TO ESTIMATING.. 2D-2 (MET) EVALUATING DIFFERENT APPROACHES TO ESTIMATING TREATMENT COSTS FROM A RANDOMIZED CLINICAL TRIAL WITH INCOMPLETE FOLLOW-UP 2E-2 (DEC) WELL-DESIGNED RISK COMMUNICATION AND VALUES.. 2E-2 (DEC) WELL-DESIGNED RISK COMMUNICATION AND VALUES CLARIFICATION METHODS IMPROVE PARENTS' DECISIONS ABOUT INFLUENZA VACCINES FOR THEIR CHILDREN 2F-2 (HSP) FACTORS ASSOCIATED WITH DECISIONS FOR.. 2F-2 (HSP) FACTORS ASSOCIATED WITH DECISIONS FOR CONTRALATERAL PROPHYLACTIC MASTECTOMY
4:45 - 5:00 2D-3 (MET) THE IMPACT OF ESTIMATING MORTALITY RATES IN.. 2D-3 (MET) THE IMPACT OF ESTIMATING MORTALITY RATES IN COST-EFFECTIVENESS ANALYSIS.: A SIMULATION STUDY 2E-3 (DEC) JOURNEY TO VACCINATION: A QUALITATIVE.. 2E-3 (DEC) JOURNEY TO VACCINATION: A QUALITATIVE EXPLORATION OF HOW BELIEFS, PERCEPTIONS AND PREVIOUS EXPERIENCES INFLUENCE VACCINATION BEHAVIOR 2F-3 (DEC) EXPLAINING THE EFFICACY OF THE BRCA GIST.. 2F-3 (DEC) EXPLAINING THE EFFICACY OF THE BRCA GIST INTELLIGENT TUTOR FOR GENETIC TESTING AND BREAST CANCER RISK
5:00 - 5:15 2D-4 (MET) RESOLVING STRUCTURAL BIAS DUE TO COMMON RANDOM.. 2D-4 (MET) RESOLVING STRUCTURAL BIAS DUE TO COMMON RANDOM NUMBERS WHEN SIMULATING EVENTS WITH NON-ORDERED OUTCOMES 2E-4 (HSP) RELATIVE BENEFITS ON HOSPITALIZATION AND.. 2E-4 (HSP) RELATIVE BENEFITS ON HOSPITALIZATION AND AVERTED HOSPITALIZATION COSTS OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) PREFERENTIAL POLICY FOR CHILDREN, AGES 2-8 2F-4 (DEC) BREAST CANCER PATIENTS' INVOLVEMENT IN.. 2F-4 (DEC) BREAST CANCER PATIENTS' INVOLVEMENT IN DECISIONS: PERSPECTIVE AND TYPE OF ADJUVANT THERAPY MATTER
5:15 - 5:30 2D-5 (MET) THEORETICAL FOUNDATION AND PRACTICAL.. 2D-5 (MET) THEORETICAL FOUNDATION AND PRACTICAL APPLICATIONS OF HALF-CYCLE CORRECTION METHODS 2E-5 (HSP) A 2-YEAR RANDOMIZED CLUSTER TRIAL TO IMPROVE.. 2E-5 (HSP) A 2-YEAR RANDOMIZED CLUSTER TRIAL TO IMPROVE CHILDHOOD INFLUENZA VACCINATION 2F-5 (DEC) THE IMPACT OF BREAST CANCER AWARENESS.. 2F-5 (DEC) THE IMPACT OF BREAST CANCER AWARENESS ADVERTISEMENTS ON WOMEN'S SELF-OBJECTIFICATION AND HEALTH BEHAVIOR
Tuesday, October 21, 2014, Day Two
10:30 - 12:00 PM
Attendees are invited to move from room-to-room
Room
Session Title 3G. COST EFFECTIVENESS IN CANCER AND CHRONIC CONDITIONS Click to view session 3H. RISK COMMUNICATION AND DECISION SUPPORT Click to view session 3I. LARGE DATA BASE ANALYSIS AND HEALTH CARE UTILIZATION Click to view session
10:30 - 10:45 3G-1 (AHE) COST-EFFECTIVENESS ANALYSIS OF PALLIATIVE TEAM.. 3G-1 (AHE) COST-EFFECTIVENESS ANALYSIS OF PALLIATIVE TEAM CARE FOR PATIENTS NEARING END-OF-LIFE 3H-1 (DEC) USE OF PATIENT DECISION AIDS IN ROUTINE CARE:.. 3H-1 (DEC) USE OF PATIENT DECISION AIDS IN ROUTINE CARE: WHAT IMPACT DOES IT HAVE ON DECISION MAKING ABOUT PROSTATE CANCER SCREENING? 3I-1 (HSP) REGIONALIZATION OF HIGH RISK SURGERIES AND ITS.. 3I-1 (HSP) REGIONALIZATION OF HIGH RISK SURGERIES AND ITS IMPLICATION ON OUTCOME AND SURGICAL CARE SUPPLY REGULATION
10:45 - 11:00 3G-2 (AHE) DNA PLOIDY ANALYSIS IS A COST-EFFECTIVE.. 3G-2 (AHE) DNA PLOIDY ANALYSIS IS A COST-EFFECTIVE ALTERNATIVE FOR CERVICAL SCREENING 3H-2 (DEC) CANCELLED: DOES ANIMATION IMPROVE COMPREHENSIO.. 3H-2 (DEC) CANCELLED: DOES ANIMATION IMPROVE COMPREHENSION OF RISK INFORMATION IN PATIENTS WITH LOW HEALTH LITERACY? 3I-2 (HSP) GEOGRAPHIC VARIATION IN RESPONSE TO FDA.. 3I-2 (HSP) GEOGRAPHIC VARIATION IN RESPONSE TO FDA WARNINGS: EVIDENCE FROM A NATIONALLY INTEGRATED SYSTEM
11:00 - 11:15 3G-3 (AHE) WHEN IS ENOUGH EVIDENCE ENOUGH? VALUE-OF-INFOR.. 3G-3 (AHE) WHEN IS ENOUGH EVIDENCE ENOUGH? VALUE-OF-INFORMATION ANALYSIS FOR PRIORITIZING ADDITIONAL OUTCOMES RESEARCH ON THE TREATMENT OF CHRONIC MYELOID LEUKEMIA 3H-3 (DEC) USING A WEB-BASED PATIENT REPORTED OUTCOMES.. 3H-3 (DEC) USING A WEB-BASED PATIENT REPORTED OUTCOMES TOOL (MYPSYCKES) TO ASSESS MENTAL HEALTH PATIENTS' INTEREST IN ALTERNATIVE THERAPIES AND RELATED CONCERNS 3I-3 (HSP) DOES OBESITY PLAY A ROLE IN THE DEVELOPMENT OF.. 3I-3 (HSP) DOES OBESITY PLAY A ROLE IN THE DEVELOPMENT OF MULTIPLE MYELOMA IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: USING DATA FROM THE UNITED STATES VETERANS HEALTH ADMINISTRATION HOSPITAL SYSTEM?
11:15 - 11:30 3G-4 (AHE) ERLOTINIB, AFATINIB, AND CISPLATIN/PEMETREXED.. 3G-4 (AHE) ERLOTINIB, AFATINIB, AND CISPLATIN/PEMETREXED FOR FIRST-LINE TREATMENT OF ADVANCED EGFR-MUTATION POSITIVE NON-SMALL CELL LUNG CANCER: VALUE-OF-INFORMATION ANALYSIS 3H-4 (DEC) USING EXPERIENCE NARRATIVES TO REDUCE.. 3H-4 (DEC) USING EXPERIENCE NARRATIVES TO REDUCE AFFECTIVE FORECASTING ERRORS 3I-4 (HSP) BEYOND SEQUENCING FOR MEDICAL PRACTICE PATTERN.. 3I-4 (HSP) BEYOND SEQUENCING FOR MEDICAL PRACTICE PATTERN ANALYSIS: THE USE OF HIERARCHICAL CLUSTER ANALYSIS WITH AN APPLICATION TO URETEROLITHIASIS
11:30 - 11:45 3G-5 (AHE) PATIENT-CENTERED SURVEILLANCE STRATEGIES FOR.. 3G-5 (AHE) PATIENT-CENTERED SURVEILLANCE STRATEGIES FOR HEPATOCELLULAR CARCINOMA: A SOCIETAL PERSPECTIVE 3H-5 (DEC) A TAILORED APPROACH TO RISK COMMUNICATION IN.. 3H-5 (DEC) A TAILORED APPROACH TO RISK COMMUNICATION IN DECISION AIDS: FINDING THE OPTIMAL FORMAT FOR INDIVIDUALS 3I-5 (HSP) USE OF CLINICAL PATHWAYS RESULTED IN LOWER.. 3I-5 (HSP) USE OF CLINICAL PATHWAYS RESULTED IN LOWER IMAGING RATES FOR A MEDICARE POPULATION
11:45 - 12:00 3G-6 (AHE) COST-EFFECTIVENESS ANALYSIS OF METASTATIC.. 3G-6 (AHE) COST-EFFECTIVENESS ANALYSIS OF METASTATIC BREAST CANCER TREATMENTS: A STUDY BASED ON THE BOLERO-2 TRIAL 3H-6 (DEC) EFFECTIVENESS OF COMPUTERIZED WEIGHT.. 3H-6 (DEC) EFFECTIVENESS OF COMPUTERIZED WEIGHT MANAGEMENT WITH PEER SUPPORTS FOR PEOPLE WITH MENTAL ILLNESS 3I-6 (HSP) DISCONTINUATION, RESTART, AND SWITCHING.. 3I-6 (HSP) DISCONTINUATION, RESTART, AND SWITCHING PATTERNS AMONG PSORIASIS PATIENTS TREATED WITH ADALIMUMAB, ETANERCEPT OR USTEKINUMAB: A UNITED STATES CLAIMS DATABASE ANALYSIS
3:30 - 5:00 PM
Attendees are invited to move from room-to-room
Room
Session Title 4J. HEART DISEASE: DECISION MAKING AND CLINICAL GUIDELINE IMPLEMENTATION Click to view session 4K. MEASUREMENT AND EXPECTATIONS Click to view session 4L. COMPARATIVE EFFECTIVENESS RESEARCH Click to view session
3:30 - 3:45 4J-1 (MET) ELICITING LIPID MANAGEMENT GUIDELINES'.. 4J-1 (MET) ELICITING LIPID MANAGEMENT GUIDELINES' VALUATION OF FUTURE LIFE 4K-1 (HSP) COMPREHENSIVELY MEASURING SUBJECTIVE.. 4K-1 (HSP) COMPREHENSIVELY MEASURING SUBJECTIVE WELL-BEING: DIMENSIONALITY ANALYSIS FOR IMPROVED OUTCOME ASSESSMENT 4L-1 (DEC) PRESENTING STOOL TESTING AS THE DEFAULT OPTION.. 4L-1 (DEC) PRESENTING STOOL TESTING AS THE DEFAULT OPTION FOR COLORECTAL CANCER SCREENING: RESULTS OF A RANDOMIZED TRIAL
3:45 - 4:00 4J-2 (HSP) THE PAY-OFF TIME FRAMEWORK: AN APPLICATION TO.. 4J-2 (HSP) THE PAY-OFF TIME FRAMEWORK: AN APPLICATION TO A NATIONAL CLINICAL GUIDELINE ON HYPERTENSION 4K-2 (DEC) UNCERTAINTY ABOUT EFFECTS IS A KEY FACTOR.. 4K-2 (DEC) UNCERTAINTY ABOUT EFFECTS IS A KEY FACTOR INFLUENCING INSTITUTIONAL REVIEW BOARDS' APPROVAL OF CLINICAL STUDIES 4L-2 (HSP) EXPLORING THE EFFECTS OF FACTORS ASSOCIATED.. 4L-2 (HSP) EXPLORING THE EFFECTS OF FACTORS ASSOCIATED WITH THE OUTCOME OF PANCREATIC CANCER SCREENING IN HIGH-RISK INDIVIDUALS BY THE USE OF A MICROSIMULATION MODEL
4:00 - 4:15 4J-3 (HSP) AUTOMATING IDENTIFICATION OF MULTIPLE CHRONIC.. 4J-3 (HSP) AUTOMATING IDENTIFICATION OF MULTIPLE CHRONIC CONDITIONS IN CLINICAL PRACTICE GUIDELINE RECOMMENDATIONS 4K-3 (DEC) DEVELOPMENT OF A MEDICAL MAXIMIZER SCALE 4K-3 (DEC) DEVELOPMENT OF A MEDICAL MAXIMIZER SCALE 4L-3 (DEC) PREVALENCE OF CLINICAL GUIDELINE-DIRECTED.. 4L-3 (DEC) PREVALENCE OF CLINICAL GUIDELINE-DIRECTED TREATMENT INTENSIFICATION IN DIABETES MELLITUS: A SYSTEMATIC REVIEW
4:15 - 4:30 4J-4 (HSP) META-ANALYSIS OF PREFERENCE-BASED QUALITY OF.. 4J-4 (HSP) META-ANALYSIS OF PREFERENCE-BASED QUALITY OF LIFE VALUES IN CORONARY HEART DISEASE 4K-4 (DEC) PARENTS BURDEN OF PEDIATRIC INFLUENZA AS A.. 4K-4 (DEC) PARENTS BURDEN OF PEDIATRIC INFLUENZA AS A CAREGIVER AND THEIR EXPECTATION TO RECEIVE ANTIBIOTIC PRESCRIPTIONS FOR THEIR CHILDREN A PILOT STUDY AT A PEDIATRIC CLINIC 4L-4 (HSP) OPTIMAL COLORECTAL CANCER SCREENING FOR A.. 4L-4 (HSP) OPTIMAL COLORECTAL CANCER SCREENING FOR A HIGHER-RISK POPULATION: THE CASE OF NORTHEASTERN PENNSYLVANIA
4:30 - 4:45 4J-5 (DEC) PATIENTS' FUTURE EXPECTATIONS ABOUT DIABETES.. 4J-5 (DEC) PATIENTS' FUTURE EXPECTATIONS ABOUT DIABETES AND HYPERTENSION: THE ON TIME STUDY 4K-5 (DEC) PERCEPTION OF SURGICAL SITE INFECTION RISK.. 4K-5 (DEC) PERCEPTION OF SURGICAL SITE INFECTION RISK FACTORS FOR SPINE SURGERY VARIES BY OPERATIVE TEAM ROLE 4L-5 (HSP) CLINICAL DECISION RULES UBIQUITOUS TO THE.. 4L-5 (HSP) CLINICAL DECISION RULES UBIQUITOUS TO THE EMERGENCY CARE SETTING ARE NOT EFFECTIVE IN RESOLVING THE BURDEN OF UNNECESSARY CT IMAGING IN WOMEN EVALUATED FOR PULMONARY EMBOLISM
4:45 - 5:00 4J-6 (HSP) COMORBIDITIES IN HEART FAILURE CAN GUIDE.. 4J-6 (HSP) COMORBIDITIES IN HEART FAILURE CAN GUIDE TREATMENT OPTIONS 4K-6 (DEC) MEASURING FEAR OF "BEING THE 1": EMOTIONAL.. 4K-6 (DEC) MEASURING FEAR OF "BEING THE 1": EMOTIONAL REACTIVITY TO THE POSSIBILITY (NOT PROBABILITY) OF RISK (HSP) IMPLEMENTATION CHALLENGES OF A COMMUNITY-BASED.. (HSP) IMPLEMENTATION CHALLENGES OF A COMMUNITY-BASED PRAGMATIC RANDOMIZED CONTROLLED TRIAL IN WOUND CARE
Wednesday, October 22, 2014, Day Three
10:00 - 11:30 AM
Attendees are invited to move from room-to-room
Room
Session Title 5M. USING MODELING TO IMPROVE RESOURCE ALLOCATION Click to view session 5N. DECISION MODELING Click to view session 5O. CLINICAL DECISION MAKING Click to view session
10:00 - 10:15 5M-1 (AHE) IN VITRO FERTILIZATION INSURANCE COVERAGE AND.. 5M-1 (AHE) IN VITRO FERTILIZATION INSURANCE COVERAGE AND CHANCES OF A LIVE BIRTH 5N-1 (MET) A DYNAMIC DECISION MODEL TO IDENTIFY.. 5N-1 (MET) A DYNAMIC DECISION MODEL TO IDENTIFY COST-EFFECTIVE POLICIES FOR CONTROLLING EPIDEMICS 5O-1 (DEC) INFERTILITY-RELATED DECISION MAKING AND.. 5O-1 (DEC) INFERTILITY-RELATED DECISION MAKING AND DECISIONAL CONFLICT
10:15 - 10:30 5M-2 (AHE) MODELING THE COST EFFECTIVENESS OF NEUROIMAGIN.. 5M-2 (AHE) MODELING THE COST EFFECTIVENESS OF NEUROIMAGING-BASED TREATMENT OF ACUTE STROKE PATIENTS WITH UNKNOWN STROKE ONSET TIME 5N-2 (MET) STRATEGIES TO PREEMPTIVELY GENOTYPE PATIENTS.. 5N-2 (MET) STRATEGIES TO PREEMPTIVELY GENOTYPE PATIENTS FOR INDIVIDUALIZED MEDICINE 5O-2 (DEC) IMPROVING PHYSICIAN DECISION-MAKING TO REDUCE.. 5O-2 (DEC) IMPROVING PHYSICIAN DECISION-MAKING TO REDUCE RISK EXPOSURE
10:30 - 10:45 5M-3 (AHE) COST-EFFECTIVENESS OF DIAGNOSTIC TESTS FOR.. 5M-3 (AHE) COST-EFFECTIVENESS OF DIAGNOSTIC TESTS FOR ASSESSING STABLE CHEST PAIN: SHOULD CARDIAC MAGNETIC RESONANCE AND CORONARY COMPUTED TOMOGRAPHY BE REIMBURSED BY A MIDDLE-INCOME COUNTRY'S PUBLIC HEALTHCARE SYSTEM? 5N-3 (MET) THE ONCOTYROL PROSTATE CANCER OUTCOME AND.. 5N-3 (MET) THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL - LESSONS LEARNED FROM NATURAL HISTORY CALIBRATION 5O-3 (HSP) DEVELOPING AND EVALUATING A WEB-BASED PATIENT.. 5O-3 (HSP) DEVELOPING AND EVALUATING A WEB-BASED PATIENT REPORTED OUTCOMES AND DECISION SUPPORT TOOL (MYPSYCKES)
10:45 - 11:00 5M-4 (AHE) HEPATITIS C PREVENTION BY SCREENING AND.. 5M-4 (AHE) HEPATITIS C PREVENTION BY SCREENING AND TREATMENT IN UNITED STATES PRISONS: AN AGENT-BASED APPROACH 5N-4 (MET) DYNAMIC NETWORK DISEASE MODELING OF THE.. 5N-4 (MET) DYNAMIC NETWORK DISEASE MODELING OF THE SYNERGISTIC TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS AND HERPES SIMPLEX VIRUS 2 5O-4 (HSP) DOES COLOR-HIGHLIGHTING CLINICAL DECISION.. 5O-4 (HSP) DOES COLOR-HIGHLIGHTING CLINICAL DECISION SUPPORT REMINDERS IMPROVE PHYSICIANS' RESPONSIVENESS?
11:00 - 11:15 5M-5 (AHE) COSTS AND OUTCOMES OF FIVE SURGICAL TREATMENTS.. 5M-5 (AHE) COSTS AND OUTCOMES OF FIVE SURGICAL TREATMENTS FOR GREAT SAPHENOUS VARICOSE VEINS: HIGH LIGATION AND STRIPPING, LASER ABLATION, RADIOFREQUENCY ABLATION, STEAM VEIN SCLEROSIS AND CYANOACRYLATE GLUE 5N-5 (MET) INCORPORATION OF PATIENT COLONIZATION WITH.. 5N-5 (MET) INCORPORATION OF PATIENT COLONIZATION WITH VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) AND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PATIENT ACUITY INTO A DISCRETE EVENT SIMULATION MODEL OF INPATIENT BED ALLOCATION AND PATIENT FLOW 5O-5 (DEC) PATIENT-SPECIFIC PHARMACOGENOMIC RESULTS.. 5O-5 (DEC) PATIENT-SPECIFIC PHARMACOGENOMIC RESULTS DELIVERED VIA A GENOMIC PRESCRIBING DECISION SUPPORT SYSTEM STRONGLY INFLUENCE PHYSICIAN MEDICATION DECISION-MAKING AND PRESCRIBING BEHAVIORS
11:15 - 11:30 5N-6 (MET) COST-EFFECTIVENESS ANALYSES THAT USE.. 5N-6 (MET) COST-EFFECTIVENESS ANALYSES THAT USE RANDOMIZED TRIALS: INSTRUMENTAL VARIABLE APPROACHES FOR HANDLING NON-COMPLIANCE 5O-6 (DEC) PERSPECTIVE INSTRUCTIONS TO INCREASE STUDENT.. 5O-6 (DEC) PERSPECTIVE INSTRUCTIONS TO INCREASE STUDENT EMPATHY IN MEDICAL DECISION MAKING